Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-08-03Clinical Trial Update: A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults [Phase 1]
This Phase 1 trial assessed the safety and potential drug interaction between casopitant and ketoconazole in healthy adults and is now compl…
-
CLINICAL_TRIALS trial_result · 2017-08-03Clinical Trial Update: The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects [Phase 1]
This Phase 1 study evaluated potential pharmacokinetic interactions when oral casopitant is co-administered with oral dolasetron, granisetro…
-
CLINICAL_TRIALS research · 2017-06-14Clinical Trial Update: Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting
This clinical trial update reports an evaluation of predictive risk factors for chemotherapy-induced nausea and vomiting (CINV).
-
FDA approval · 2017-05-31FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) from Merck Sharp & Dohme LLC.
-
FDA approval · 2017-05-31FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (aprepitant) filed by Merck Sharp & Dohme LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients [NA]
The clinical trial NCT02403037 evaluating auricular acupressure to prevent chemotherapy-induced nausea and vomiting in female breast cancer …
-
FDA label_change · 2017-05-25FDA Approved: DRONABINOL — Supplemental Application (Wellhouse Pharma, LLC)
FDA approved a supplemental application for dronabinol from Wellhouse Pharma, LLC (NDA205525).
-
CLINICAL_TRIALS research · 2017-05-15Clinical Trial Update: Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594) [Phase 4]
Phase 4 clinical trial evaluating palonosetron plus dexamethasone to prevent chemotherapy-induced nausea and vomiting in moderately emetogen…
-
CLINICAL_TRIALS trial_result · 2017-05-05Clinical Trial Update: Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) [Phase 3]
This clinical trial update reports the completion of a Phase 3 study of MK0869 for the prevention of chemotherapy-induced nausea and vomitin…
-
CLINICAL_TRIALS trial_result · 2017-04-24Clinical Trial Update: Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) [Phase 4]
Phase 4 trial update showing completion of a study evaluating aprepitant to prevent chemotherapy-induced nausea and vomiting in patients rec…
-
CLINICAL_TRIALS trial_result · 2017-04-19Clinical Trial Update: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents [Phase 2]
A Phase 2 trial assessing the relative bioavailability of an extemporaneous aprepitant suspension in adolescents for chemotherapy-induced na…
-
CLINICAL_TRIALS trial_result · 2017-03-30Clinical Trial Update: Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting [Phase 3]
A Phase 3 trial evaluated a quadruple antiemetic combination (aprepitant, olanzapine, palonosetron, and dexamethasone) for preventing chemot…
-
CLINICAL_TRIALS trial_result · 2017-03-30Clinical Trial Update: Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy [Phase 2]
This Phase 2 pilot trial evaluated adding olanzapine and aprepitant to standard antiemetic therapy to prevent nausea and vomiting in pediatr…
-
FDA approval · 2017-03-30FDA Approved: ONDANSETRON — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark Pharmaceuticals’ supplemental application for ondansetron (generic antiemetic) under ANDA077535.
-
FDA label_change · 2017-03-27FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for ondansetron from PAI Pharma, resulting in changes to the product labeling.
-
FDA approval · 2017-03-27FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for ondansetron submitted by Rising Pharma Holdings, Inc.
-
FDA approval · 2017-03-24FDA Approved: ONDANSETRON — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for ondansetron from Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2017-03-24FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ondansetron hydrochloride from Sun Pharmaceutical Industries, Inc., under the ANDA.
-
FDA approval · 2017-02-14FDA Approved: ONDANSETRON — Supplemental Application (ACTAVIS PHARMA, INC.)
The FDA approved a supplemental application for ondansetron tablets from Actavis Pharma, Inc. under the ANDA, signifying an approved change …
-
FDA approval · 2017-02-07FDA Approved: ONDANSETRON — Supplemental Application (AvPAK)
FDA approves a supplemental application for ondansetron submitted by AvPAK.
-
CLINICAL_TRIALS trial_result · 2017-02-06Clinical Trial Update: Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients [Phase 2]
Phase 2 trial evaluating a combination of palonosetron, ondansetron, and dexamethasone for preventing delayed chemotherapy-induced nausea an…
-
CLINICAL_TRIALS trial_result · 2016-12-28Clinical Trial Update: A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC [Phase 3]
Phase 3 multicenter trial evaluating APF530 (granisetron) given subcutaneously to prevent chemotherapy-induced nausea and vomiting in patien…
-
FDA label_change · 2016-12-28FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental labeling application for AKYNZEO (netupitant and palonosetron) submitted by Helsinn Therapeutics (U.S.), Inc., u…
-
FDA approval · 2016-12-02FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) from Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2016-11-23Clinical Trial Update: Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN [NA]
A proof-of-concept clinical trial is testing palonosetron and olanzapine without dexamethasone to prevent chemotherapy-induced nausea and vo…